Tech Mahindra And NVIDIA Unveil AI-Driven Pharmacovigilance Solution To Enhance Drug Safety Processes

In a significant stride toward enhancing drug safety management, Tech Mahindra has introduced a groundbreaking pharmacovigilance solution powered by NVIDIA's advanced AI technology.

This innovative solution is set to redefine the pharmacovigilance landscape by employing agentic AI and automation to improve the accuracy, speed, and efficiency of drug safety processes. It aims to tackle the industry's pressing issues, such as data overload and manual processing delays, thereby streamlining the management of adverse drug reactions (ADRs).

The collaboration between Tech Mahindra and NVIDIA brings a new level of intelligence to pharmacovigilance, aiming for better patient outcomes. The industry, tasked with managing over a thousand ADR cases daily for major drugs, greatly benefits from this partnership.

The autonomous AI-driven solution significantly reduces human intervention in the reporting and processing of ADRs. By automatically flagging, prioritizing, and handling ADR reports, the solution cuts down on potential delays and errors. Impressively, it boasts up to a 40% reduction in turnaround times, a 30% increase in data accuracy, and a 25% reduction in operational costs. This improvement not only ensures quicker case processing and adherence to regulations but also shifts pharmacovigilance from a reactive to a predictive approach.

Nikhil Malhotra, Chief Innovation Officer & Global Head of AI and Emerging Technologies at Tech Mahindra, emphasized the transformative impact of their collaboration with NVIDIA. "As the pharmaceutical industry navigates volumes of data during trials and post-launch, our collaboration with NVIDIA leverages generative AI and multi-agent systems to streamline pharmacovigilance process. Together, we are revolutionizing drug safety management and using the innovative AI-driven framework to develop multiple use cases for our global customers." This partnership exemplifies how leveraging generative AI and multi-agent systems can significantly enhance the efficiency and effectiveness of pharmacovigilance processes.

At the heart of this solution is Tech Mahindra's TENO framework, which incorporates NVIDIA's AI Enterprise software platform. This includes tools like NVIDIA NeMo™ for conversational AI, NIM™ microservices for intelligent workflows, and AI Blueprints for streamlined operations.

The integration of these NVIDIA technologies allows for the automation of key pharmacovigilance tasks such as case intake, data transformation, quality control, and compliance management.

Furthermore, the solution employs LLM-powered AI agents that autonomously manage case classification, prioritization, and the verification of pharmacovigilance emails, significantly reducing the likelihood of human error.

John Fanelli, Vice President of Enterprise Software at NVIDIA, highlighted the role of AI in drug safety, stating, "AI is ideal for monitoring medicines throughout their lifecycle to support safety. Integrating AI into the Tech Mahindra TENO framework with NVIDIA AI Enterprise software enhances pharmacovigilance by augmenting human capabilities to help identify potential safety issues more effectively." This integration not only bolsters the capabilities of pharmacovigilance professionals but also ensures a more reliable monitoring of medicines throughout their lifecycle.

To further enhance its capabilities, Tech Mahindra has expanded the TENO framework to include NVIDIA AI Enterprise. This expansion enriches the framework with customized AI agents tailored to tackle a wide array of industry challenges. By incorporating NVIDIA NeMo™, the framework accelerates the generative AI pipeline for efficient data collection and curation.

Coupled with Tech Mahindra's VerifAI solution for data validation and governance, the framework ensures the integrity and accuracy of pharmacovigilance data. The distributed training and model customization capabilities within the framework allow AI models to continuously evolve, thereby improving the precision of decision-making processes in drug safety management.

By harnessing the power of agentic AI and automation, this innovative solution is set to transform drug safety management. With enhanced accuracy, speed, and efficiency, it addresses the critical challenges facing the industry today.

The collaborative efforts of Tech Mahindra and NVIDIA not only streamline the pharmacovigilance process but also pave the way for more predictive and proactive drug safety practices.